We retrospectively analyzed the outcomes of 1837 adults and children with severe aplastic ane- 
tuzumab as possible options. 7, 14 Recent reports from the UK using alemtuzumab as serotherapy in the conditioning regimen in both MSD and MUD transplantation for SAA have shown remarkably low rates of chronic GvHD compared with historical series. 15, 16 However, previous attempts to determine the optimal serotherapy regimen in SAA have been hampered by small numbers. 2, 9 In order to investigate the optimal serotherapy regimen for HSCT for idiopathic SAA and its impact on main transplant outcomes, we and dosing schedule of ATG, and details of immunosuppression were not available for analysis.
| Study endpoints
The primary study endpoint was the risk of chronic GvHD. Any grade of GvHD from day 100 was included. Secondary endpoints included overall survival, graft failure and acute GvHD (grades II-IV). Event free survival (EFS) was defined as the absence of engraftment, graft loss, second transplant, malignancy following transplant, relapse, and death.
Diagnosis of acute of chronic GvHD was made by individual centers. without TBI). Adjusted effects on overall survival, EFS, and chronic GvHD incidence were estimated in terms of hazard ratios using the Cox model with a shared random center effect ("frailty model") to take into account unmeasured confounders related to belonging to the same center. Modification of the effect of the conditioning treatment in subgroups was explored including interaction terms.
| Statistical analysis
Adjusted effects on the occurrence of acute GvHD were estimated in terms of Odds Ratios (ORs) using multinomial logistic regression, results are reported in terms of the OR of developing acute GvHD rather than being event-free at day 100: OR > 1 indicates a risk factor for acute GvHD while OR < 1 indicates a protective factor. All P-values shown are from 2-sided tests and the reported CIs refer to 95% boundaries. A significance level 5% was considered for all tests, except that for interactions were 10% was applied.
| RESULTS
The characteristics of the patients and their transplantations are summarized in Table 1 . A total of 1837 patients were eligible for analysis: In the ATG and NS group the commonest conditioning regimen was cyclophosphamide alone, in contrast to the alemtuzumab group which more commonly received fludarabine/cyclophosphamide (65.5%). More patients received alemtuzumab in their conditioning regimen as part of a MUD transplant than a MSD transplant (73.9% vs 26.1%). This finding was reversed in the ATG and NS group.
| Hematopoietic recovery
In each of the 3 treatment groups, patients were categorized as having engrafted, or as having primary or secondary graft failure. Overall, 1617 of 1816 (89%) patients successfully engrafted. Failure to engraft (ie, the sum of primary and secondary graft failure) was not significantly different between the ATG, alemtuzumab and NS groups:
11.3%, 9.6% and 10.7%, respectively (P = .732).
| Acute and chronic GvHD
Observed rates of grades 2-4 acute GvHD in the ATG, alemtuzumab and NS group were 13.3%, 6.7%, and 19.1% respectively (P < .001). This difference in the observed rates of acute GvHD was significantly reduced in favor of alemtuzumab compared with ATG (P = .012) and NS (P < .001). Other variables associated with a higher probability of developing acute GvHD included MUD transplant and use of PB as source of stem cells: adjusted OR were 2.79 (P < .001) for MUD vs MSD transplantation and 1.49 (P = .011) for PB vs BM source. By multivariate analysis, when compared with ATG, alemtuzumab was associated with a lower risk of acute GvHD (OR 0.262; 95% CI 0.14-0.47; P < .001). When compared with ATG, receiving NS led to a higher probability of developing acute GVHD (OR 1.647; 95% CI 1.12-2.41; P = .010), whereas the use of alemtuzumab significantly reduced the risk of acute GvHD compared with NS (OR 0.159; 95% CI 0.08-0.31, P = .000). Figure 1A shows the cumulative incidence (CI) of chronic GvHD.
A total of 1213 patients (n = 1213, 66%) were evaluable for analysis:
15% of patients (n = 283) were not considered at risk of chronic GvHD as they did not reach day 100 alive and event free. Missing 
| Overall survival
The 5-year cumulative probability of OS in the ATG, alemtuzumab and NS groups was 80.2% (95% CI 77.7%-82.7%), 81.5% (95% CI 76.1%-86.8%), and 72.5% (95% CI 67.1%-78.0%), respectively (P = .021) ( Figure 1B) . OS was significantly better in both ATG and alemtuzumab patients compared with NS (P = .010 and .025, respectively). However, comparison between ATG and alemtuzumab failed to reach significance (P = .604). Factors significantly associated with OS in multivariate analysis included age, donor source and type of serotherapy (Table 3) . In multivariate analysis, alemtuzumab was associated with a significantly increased OS in comparison to NS transplants (HR 0.48; 95% CI 0.32-0.74, P = .001) and a trend towards significance against ATG transplants (0.73; 95% CI 0.51-1.04, P = .081).
| Event free survival
There was no difference in the rates of EFS across the 3 groups: the cumulative probability of achieving 5-year EFS was 71.8% in the ATG group (95% CI 68.9-74.6), 73.2% in the alemtuzumab-treated group (95% CI 66.9-79.4) and 68.3% in the group that received NS (95% CI 62.6-74.0; P = .393) ( Figure 1C ).
| Causes of death
Causes of death are categorized in Supplementary material, table 1.
In all treatment groups, infection was the most common cause of death and accounted for 30.7%-47.6% of deaths. There was no significant difference between the causes of death across the different types of serotherapy (P = .131).
| DISCUSSION
This study is the largest analysis to document transplant outcomes after in vivo T-cell depletion (alemtuzumab or ATG) for adults and children with idiopathic SAA compared with T-cell replete HSCT. Retrospective data suggests that ATG improves survival. 13 However, the optimal strategy for in vivo T-cell depletion is uncertain. This is of particular importance as GvHD remains the most unwanted complication after HSCT in AA; furthermore chronic GVHD is a major factor in reducing long term survival in SAA HSCT survivors. 20 These data are in agreement with those reported by other groups, consistent with similarly low rates of chronic GvHD with alemtuzumab-based regimens; and this is associated with stable mixed T-cell chimerism that persists on withdrawal of post graft immunosuppression. 15, 16, 20 The superior outcomes for acute and chronic GvHD seen with alemtuzumab compared with ATG could potentially be explained by a greater T-cell depletion. Whereas historically this would have led to a greater incidence of infections due to delayed immune reconstitution, this may no longer be the case because of advances in supportive care. Infection was the most common cause of death, with a trend for Abbreviation: HR, hazard ratio, 95% CI, P-value.
Age, continuous, effect associated to +1 year of age. a Gender mismatch = male patient and female donor vs other combinations.
more infections in patients receiving serotherapy vs NS. There is a 
